A5053155157- Peripheral Neuropathies and Disorders
- Acute Ischemic Stroke Management
- Autoimmune Neurological Disorders and Treatments
- Multiple Sclerosis Research Studies
- S100 Proteins and Annexins
- Inflammatory Myopathies and Dermatomyositis
- Nematode management and characterization studies
- Glycogen Storage Diseases and Myoclonus
- Traumatic Brain Injury and Neurovascular Disturbances
- Amyotrophic Lateral Sclerosis Research
- Palliative Care and End-of-Life Issues
- Healthcare Decision-Making and Restraints
- Cerebrovascular and Carotid Artery Diseases
- Eosinophilic Disorders and Syndromes
- Fungal Infections and Studies
- Neurological and metabolic disorders
- Infective Endocarditis Diagnosis and Management
- Protein Tyrosine Phosphatases
- Electrolyte and hormonal disorders
- Cerebrovascular and genetic disorders
- Family and Disability Support Research
- Venous Thromboembolism Diagnosis and Management
- Sarcoidosis and Beryllium Toxicity Research
- Genetics and Neurodevelopmental Disorders
- Atrial Fibrillation Management and Outcomes
The University of Sydney
2017-2024
Teva Pharmaceuticals (Australia)
2024
Novartis (Australia)
2024
Royal North Shore Hospital
2015-2024
Northern Sydney Local Health District
2019-2023
Liverpool Hospital
2019-2022
UNSW Sydney
2020
Alberta Bible College
2019
Australian National University
2009-2015
Canberra Hospital
2013-2014
ABSTRACT: Background: Endovascular thrombectomy (EVT) has shown efficacy in acute ischemic stroke (AIS) patients with infective endocarditis (IE). The possibility to undertake advanced histopathological clot analysis following EVT offers a new avenue establish the etiological basis of – which is often labelled “cryptogenic.” In this paper, we present our findings from four consecutive IE who underwent an AIS at tertiary referral comprehensive centre. Methods: Comprehensive retrieved after...
Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms multiple sclerosis and associated with secondary autoimmune adverse events. We report novel case myositis that occurred seven months after initial cycle achieved full recovery oral corticosteroids. This particular form appears to be unique, likely distinct entity from other four types immune-mediated myositis.
Background Siponimod is approved for use in people with secondary progressive multiple sclerosis (pwSPMS). An integrated digital platform, MSGo, was developed pwSPMS and clinicians to help navigate the steps of pre-siponimod work-up. Objective To explore real-world onboarding experiences siponimod amongst Australia. Methods Retrospective, non-interventional, longitudinal, analysis data extracted from MSGo (20 April 2022). The primary endpoint average time onboarding; endpoints were adherence...
Background. The significance of the Hyperdense Middle Cerebral Artery Sign (HMCAS) is uncertain. Aims. This prospective study investigated sensitivity, specificity, prevalence, prognosis, interobserver variability, and associated clinical features HMCAS in acute ischemic stroke. Methods. Initial CT scans 117 patients with stroke or transient attack (TIA) 65 age-matched controls were reported independently by two neuroradiologists blinded to diagnosis. Details initial severity comorbidities...
The hyperdense middle cerebral artery sign (HMCAS) is a useful clinical in the management of acute stroke and may alter time-critical decisions within an emergency setting. Though gold standards have been published, these are rarely used practice scans tend to be reported subjectively. It therefore possible that level experience doctor reporting scan impact on accuracy hence patient management. This study was designed evaluate detecting HMCAS across doctors with varying levels...
Motor neuron disease (MND) is a neurodegenerative disorder leading to functional decline and death. Multidisciplinary MND clinics provide an integrated approach management facilitate discussion on advanced care directives (ACDs). The study objectives are analyse (1) the prevalence of ACD in our clinic, (2) relationship between patient demographics (3) decision-making variables such as NIV, PEG, hospital admissions location death.Using clinic records, all patients who attended Liverpool...
<h3>Objectives</h3> Neurosarcoidosis may present with longitudinally extensive transverse myelitis (LETM) posing a diagnostic challenge. We describe the clinical features, radiology and management of five patients spinal neurosarcoidosis (SNS). <h3>Methods</h3> retrospectively identified diagnosis SNS clinical, radiological pathological data were reviewed. <h3>Results</h3> There three females two males who were, on average, 49 years at onset. A histopathological sarcoid was confirmed in...
<h3>Objectives</h3> Progressive supranuclear palsy (PSP) is a neurodegenerative condition characterised by Parkinsonian features, cervical dystonia and ophthalmoparesis. Paraneoplastic PSP has previously been reported in the literature association with several different cancer types but very rare.<sup>1–3</sup> <h3>Methods</h3> Case review. <h3>Results</h3> A 74 year old Chinese man was diagnosed Stage 1b EGFR positive lung adenocarcinoma underwent left upper lobectomy. Twelve months later...
<h3>Objectives</h3> Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Pre-screen requirements siponimod include CYP2C9 genotype testing. To support onboarding, a digital platform, 'MSGo', was developed by Novartis and RxMx® Healthcare Professionals their patients. Here, data derived exclusively from MSGo utilised to characterise the onboarding experience of patients Australia. <h3>Methods</h3> The study enrolled >350 SPMS registered...
<h3>Objectives</h3> We describe the case of a 44-year-old female who developed previously unreported, corticosteroid-responsive, autoimmune, non-necrotising myositis after receiving alemtuzumab for relapsing remitting multiple sclerosis (RRMS). <h3>Methods</h3> A with 13 year history RRMS was treated in November 2015. Her baseline EDSS at time treatment 1.5 MRI showing widespread demyelination affecting deep white matter brain, optic nerves and spinal cord. There were no acute complications...
<h3>Objectives</h3> Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Initiating siponimod involves prescreening tests, including a <i>CYP2C9</i> genotype test to determine dosing. To support onboarding, an integrated digital platform, 'MSGo', was developed by Novartis and RxMx<sup>®</sup> Healthcare Professionals patients. Here, data derived exclusively from MSGo used characterise onboarding of patients Australia. <h3>Methods</h3> The study...
<h3>Introduction</h3> Central Pontine Myelinolysis (CPM) is a demyelinating disorder affecting the central pons linked to osmotic stress and hyponatremia. Cases in pregnancy have been associated with hyperemesis gravidarum, but also other fluctuations electrolyte metabolic balance.<sup>1</sup> <h3>Case</h3> A 22-year-old lady presented at 34 weeks (G2P0) severe headache. Pregnancy that date had unremarkable detailed neurological examination was unremarkable. MRI performed revealing pontine...
<h3>Background</h3> Autoimmune encephalitis is an increasingly recognised disease that presents with seizures, neuropsychiatric symptoms, dystonic movements, and autonomic dysfunction<sup>1</sup>. As the mainstay of treatment immunosuppressive therapies are most effective when subject to early initiation timely escalation, both which affect outcomes<sup>2</sup>. Nevertheless approximately half patients NMDA-R antibody do not respond adequately first-line therapy, a significant proportion...